SG50636A1 - Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof - Google Patents

Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof

Info

Publication number
SG50636A1
SG50636A1 SG1996007427A SG1996007427A SG50636A1 SG 50636 A1 SG50636 A1 SG 50636A1 SG 1996007427 A SG1996007427 A SG 1996007427A SG 1996007427 A SG1996007427 A SG 1996007427A SG 50636 A1 SG50636 A1 SG 50636A1
Authority
SG
Singapore
Prior art keywords
heterocyclylisoquinolinium
salts
substituted
compositions
substituted heterocyclylisoquinolinium
Prior art date
Application number
SG1996007427A
Inventor
Charapani Subramanyam
John Alan Dority Jr
John MALLAMO
Mattew Steven Miller
Virendra Kumar
William George Earley
Original Assignee
Sterling Winthrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterling Winthrop Inc filed Critical Sterling Winthrop Inc
Publication of SG50636A1 publication Critical patent/SG50636A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG1996007427A 1993-09-14 1994-09-10 Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof SG50636A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12138993A 1993-09-14 1993-09-14
US08/283,319 US5569655A (en) 1993-09-14 1994-07-29 Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof

Publications (1)

Publication Number Publication Date
SG50636A1 true SG50636A1 (en) 1998-07-20

Family

ID=26819410

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996007427A SG50636A1 (en) 1993-09-14 1994-09-10 Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof

Country Status (8)

Country Link
US (2) US5569655A (en)
EP (1) EP0647641A1 (en)
JP (1) JPH07224065A (en)
AU (1) AU685821B2 (en)
CA (1) CA2131967A1 (en)
HU (1) HUT68092A (en)
MX (1) MXPA94007014A (en)
SG (1) SG50636A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6676834B1 (en) * 1998-01-28 2004-01-13 James Benenson, Jr. Self-cleaning water filter
CA2479036A1 (en) * 2002-03-13 2003-09-18 Euro-Celtique S.A. Aryl substituted pyrimidines and the use thereof
US7605264B2 (en) * 2004-01-16 2009-10-20 Bristol-Myers Squibb Company Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7253283B2 (en) * 2004-01-16 2007-08-07 Bristol-Myers Squibb Company Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7569689B2 (en) * 2004-01-16 2009-08-04 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7625921B2 (en) * 2004-01-16 2009-12-01 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7326728B2 (en) * 2004-01-16 2008-02-05 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof
US7273881B2 (en) * 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
CN102558082B (en) 2004-03-05 2015-09-30 日产化学工业株式会社 Isoxazoline-substituted benzamide compound prepare intermediate
US7361654B2 (en) 2005-01-13 2008-04-22 Bristol-Myers Squibb Co. Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7642273B2 (en) * 2005-01-13 2010-01-05 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7411071B2 (en) * 2005-01-13 2008-08-12 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
JP2007084458A (en) * 2005-09-20 2007-04-05 Chemiprokasei Kaisha Ltd 1,8-naphthyridine derivative and organic electroluminescent element comprising the same
CN101580583B (en) * 2009-06-26 2011-03-30 金发科技股份有限公司 Method for preparing poly aryl ether ketone copolymers by adopting quaternary copolymerization technique
NO2482815T3 (en) * 2009-10-02 2018-09-29
AU2015268638B2 (en) * 2009-10-02 2017-08-31 Avexxin As Anti inflammatory 2-oxothiazoles and 2-oxooxazoles
CA2899137C (en) 2013-01-29 2021-07-13 Avexxin As Antiinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
US9409872B1 (en) * 2015-02-16 2016-08-09 Mark Quang Nguyen Fumarate compounds, pharmaceutical compositions thereof, and methods of use
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
EP3523287B1 (en) 2016-10-04 2021-09-01 Merck Sharp & Dohme Corp. Benzo[b]thiophene compounds as sting agonists
MA49772A (en) 2017-08-04 2021-04-21 Merck Sharp & Dohme STING THIOPHENE BENZO [B] AGONISTS FOR CANCER TREATMENT
JP2020529421A (en) 2017-08-04 2020-10-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Combination of PD-1 antagonist and benzo [b] thiophene STING agonist for the treatment of cancer
US10793557B2 (en) * 2018-04-03 2020-10-06 Merck Sharp & Dohme Corp. Sting agonist compounds
WO2019195063A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
JP7519464B2 (en) 2020-05-05 2024-07-19 ヌバレント， インク． Heteroaromatic macrocyclic ether chemotherapeutic agents
JP7519463B2 (en) 2020-05-05 2024-07-19 ヌバレント， インク． Heteroaromatic macrocyclic ether chemotherapeutic agents
KR20240087788A (en) 2021-10-01 2024-06-19 뉴베일런트, 아이엔씨. Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180831A (en) * 1990-08-10 1993-01-19 Georgia Tech Research Corporation Quaternary pyridinium compounds
US5240939A (en) * 1991-10-31 1993-08-31 Anaquest, Inc. Nitrogen bridge tetrahydroisoquinolines

Also Published As

Publication number Publication date
US5569655A (en) 1996-10-29
EP0647641A1 (en) 1995-04-12
US5604224A (en) 1997-02-18
AU685821B2 (en) 1998-01-29
MXPA94007014A (en) 2005-03-25
JPH07224065A (en) 1995-08-22
HU9402629D0 (en) 1994-11-28
AU7294194A (en) 1995-03-30
CA2131967A1 (en) 1995-03-15
HUT68092A (en) 1995-05-29

Similar Documents

Publication Publication Date Title
SG50636A1 (en) Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
GB9422571D0 (en) Haemorrihoidal compositions and method of use
IL104007A0 (en) Adhesive composition and method of using it
GB2294465A8 (en) Perfluoroelastomeric compositions and methods
IL117872A0 (en) Herbicidal compositions and method of their use
HU9401580D0 (en) Method for the preparation and popification of alphia - interferon
EP0707480A4 (en) Antineoplastic compositions and methods of use
HU9600241D0 (en) Mutable composition and methods of use thereof
GB9407640D0 (en) Coating compositions and method of formimg
PL298230A1 (en) Fusible adhesive composition and method of using same
NZ312748A (en) Synergistic herbicidal composition and method of use thereof
GB9414227D0 (en) Antiperspirant composition and method of use thereof
PL311268A1 (en) Cholestyramine containing composition and method of obtaining same
ZA897446B (en) Antimicrobial composition and method of use
EP0585168A3 (en) Composition and methods for the generation of bone
SG49910A1 (en) Substituted 6,11-ethano-6,11-dihydroenzo(B)quinolizinium salts and composition and methods of use thereof
GB2294637B (en) Therapeutic compositions and methods of use
ZA9410004B (en) Aminosulphonyl-phenyl-1h-pyrrole derivatives method of their preparation and their use
GB9108043D0 (en) Method for the formation of liposomes and compositions for use therein
GB9224295D0 (en) Method and composition
AU3422393A (en) Novel RXR-containing heterodimers and method of use
AU7294294A (en) 12-hetero substituted 6,11-ethano-6,11-dihydrobenzo(b) quinolizinium salts and compositions and method of use thereof
PL303822A1 (en) Therapeutic compositions containing ipsapyrone and method of obtaining them
GB9308051D0 (en) Method and composition
SG66305A1 (en) Composition and method for treatment of phoshated surfaces